what is a glp 1 receptor Glucagon-like peptide-1 Frontiers | GLP-1 receptor agonist
Description
A slower dose escalation, a temporary dose reduction, or a switch to a different GLP-1 medication may be necessary
19,103 However, a prominent adverse effect of TZDs is weight gain, thought to be primarily caused by a rise in body fat and retention of fluids
Cardiovascular outcomes trials of Incretin-Based therapies
If you experience any of the following, remain at your current dose for an additional 2 to 4 weeks before escalating: Nausea lasting more than 3 days after injection Vomiting more than once per week Inability to maintain adequate caloric intake (under 1,000 calories daily) Signs of dehydration despite increased fluid intake New onset of significant fatigue that interferes with daily function Slowing escalation is not failure
Novo Nordisk received approval for its Wegovy weight-loss pill in December, and its been on the market for a few months
Cagrilintide showed a higher rate of injection site reactions compared to placebo, including mild redness and irritation
